Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer

DMM Disease Models and Mechanisms

Volumn 8, Issue 3, 2015, Pages 237-251

  Johnstone, Cameron N ^a,b,c   Smith, Yvonne E ^d   Cao, Yuan ^a   Burrows, Allan D ^a   Cross, Ryan S N ^a   Ling, Xiawei ^a   Redvers, Richard P ^a   Doherty, Judy P ^a   Eckhardt, Bedrich L ^a,e   Natoli, Anthony L ^a   Restall, Christina M ^a   Lucas, Erin ^a   Pearson, Helen B ^a   Deb, Siddhartha ^f   Britt, Kara L ^a,b   Rizzitelli, Alexandra ^a   Li, Jason ^a   Harmey, Judith H ^d   Pouliot, Normand ^a,b,c   Anderson, Robin L ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^e UNIVERSITY OF TEXAS   (United States)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Breast cancer; Estrogen receptor alpha; Metastasis; Syngeneic preclinical models; Tumour subtyping

Indexed keywords

CALGRANULIN A; CD36 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PARATHYROID HORMONE LIKE HORMONE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P53; STROMELYSIN; TAMOXIFEN; THROMBOSPONDIN RECEPTOR; UNCLASSIFIED DRUG; MESSENGER RNA; TUMOR MARKER; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST TUMOR; C57BL 6 MOUSE; CELL NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; EO771 CELL LINE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TP53 GENE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CLASSIFICATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; MAMMARY NEOPLASMS, ANIMAL; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHENOTYPE; RNA, MESSENGER; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84929157819     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.017830     Document Type: Article

References (109)

1. Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E. et al. (2012). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165-178.
2. Antoniou, A. C., Kuchenbaecker, K. B., Soucy, P., Beesley, J., Chen, X., McGuffog, L., Lee, A., Barrowdale, D., Healey, S., Sinilnikova, O. M. et al.; CIMBA, SWEBRCA; HEBON; EMBRACE; GEMO Collaborators Study; kConFab Investigators (2012). Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res. 14, R33.
3. Arai, K., Takano, S., Teratani, T., Ito, Y., Yamada, T. and Nozawa, R. (2008). S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr. Cancer Drug Targets 8, 243-252.
4. Aslakson, C. J. and Miller, F. R. (1992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399-1405.
5. Atkinson, K. E. (1989). An Introduction to Numerical Analysis. New York, NY: John Wiley and Sons.
6. Bernhard, E. J., Gruber, S. B. and Muschel, R. J. (1994). Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA 91, 4293-4297.
7. Bhowmick, N. A., Neilson, E. G. and Moses, H. L. (2004). Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337.
8. Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., van Leeuwen, F. E., Wesseling, J., Cheang, M. C., Gelmon, K., Nielsen, T. O., Blomqvist, C. et al. (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7, e1000279.
9. Bryant, E. C. (1983). Area-Under-the-Curve Analysis and Other Analysis Strategies for Repeated Measures Clinical Trials. Dissertation for Doctor of Public Health, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
10. Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S. et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502.
11. Casey, A. E., Laster, W. R., Jr and Ross, G. L. (1951). Sustained enhanced growth of carcinoma EO771 in C57 black mice. Proc. Soc. Exp. Biol. Med. 77, 358-362.
12. Cheang, M. C., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M. and Nielsen, T. O. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14, 1368-1376.
13. Chia, J., Kusuma, N., Anderson, R., Parker, B., Bidwell, B., Zamurs, L., Nice, E. and Pouliot, N. (2007). Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer. Am. J. Pathol. 170, 2135-2148.
14. Coussens, L. M. and Werb, Z. (1996). Matrix metalloproteinases and the development of cancer. Chem. Biol. 3, 895-904.
15. Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I. et al. (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 106, 13820-13825.
16. Curtis, C., Shah, S. P., Chin, S. F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., Yuan, Y. et al.; METABRIC Group (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352.
17. de Ronde, J. J., Hannemann, J., Halfwerk, H., Mulder, L., Straver, M. E., Vrancken Peeters, M. J., Wesseling, J., van de Vijver, M., Wessels, L. F. and Rodenhuis, S. (2010). Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res. Treat. 119, 119-126.
18. DeFilippis, R. A., Chang, H., Dumont, N., Rabban, J. T., Chen, Y. Y., Fontenay, G. V., Berman, H. K., Gauthier, M. L., Zhao, J., Hu, D. et al. (2012). CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. 2, 826-839.
19. Denoyer, D., Potdevin, T., Roselt, P., Neels, O. C., Kirby, L., Greguric, I., Katsifis, A., Dorow, D. S. and Hicks, R. J. (2011). Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J. Nucl. Med. 52, 115-122.
20. Denoyer, D., Kusuma, N., Burrows, A., Ling, X., Jupp, L., Anderson, R. L. and Pouliot, N. (2014). Bone-derived soluble factors and laminin-511 cooperate to promote migration, invasion and survival of bone-metastatic breast tumor cells. Growth Factors 32, 63-73.
21. DeRose, Y. S., Wang, G., Lin, Y. C., Bernard, P. S., Buys, S. S., Ebbert, M. T., Factor, R., Matsen, C., Milash, B. A., Nelson, E. et al. (2011). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514-1520.
22. Doi, M., Thyboll, J., Kortesmaa, J., Jansson, K., Iivanainen, A., Parvardeh, M., Timpl, R., Hedin, U., Swedenborg, J. and Tryggvason, K. (2002). Recombinant human laminin-10 (alpha5beta1gamma1). Production, purification, and migration-promoting activity on vascular endothelial cells. J. Biol. Chem. 277, 12741-12748.
23. Dontu, G., Abdallah, W. M., Foley, J. M., Jackson, K. W., Clarke, M. F., Kawamura, M. J. and Wicha, M. S. (2003). In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270.
24. Dowsett, M., Smith, I., Robertson, J., Robison, L., Pinhel, I., Johnson, L., Salter, J., Dunbier, A., Anderson, H., Ghazoui, Z. et al. (2011). Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J. Natl. Cancer Inst. Monogr. 2011, 120-123.
25. Eckhardt, B. L., Parker, B. S., van Laar, R. K., Restall, C. M., Natoli, A. L., Tavaria, M. D., Stanley, K. L., Sloan, E. K., Moseley, J. M. and Anderson, R. L. (2005). Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol. Cancer Res. 3, 1-13.
26. Eckhardt, B. L., Francis, P. A., Parker, B. S. and Anderson, R. L. (2012). Strategies for the discovery and development of therapies for metastatic breast cancer. Nat. Rev. Drug Discov. 11, 479-497.
27. Ehrchen, J. M., Sunderkötter, C., Foell, D., Vogl, T. and Roth, J. (2009). The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukoc. Biol. 86, 557-566.
28. Einav, U., Tabach, Y., Getz, G., Yitzhaky, A., Ozbek, U., Amariglio, N., Izraeli, S., Rechavi, G. and Domany, E. (2005). Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 24, 6367-6375.
29. Ellis, S., Killender, M. and Anderson, R. L. (2000). Heat-induced alterations in the localization of HSP72 and HSP73 as measured by indirect immunohistochemistry and immunogold electron microscopy. J. Histochem. Cytochem. 48, 321-331.
30. Fleming, N. I., Trivett, M. K., George, J., Slavin, J. L., Murray, W. K., Moseley, J. M., Anderson, R. L. and Thomas, D. M. (2009). Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. Cancer Res. 69, 7473-7479.
31. Förster, C., Mäkela, S., Wärri, A., Kietz, S., Becker, D., Hultenby, K., Warner, M. and Gustafsson, J. A. (2002). Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. USA 99, 15578-15583.
32. rd Annual Meeting, Vol. 72, pp. 2464. Chicago, IL: AACR.
33. Gazinska, P., Grigoriadis, A., Brown, J. P., Millis, R. R., Mera, A., Gillett, C. E., Holmberg, L. H., Tutt, A. N. and Pinder, S. E. (2013). Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod. Pathol. 26, 955-966.
34. Ghazoui, Z., Buffa, F. M., Dunbier, A. K., Anderson, H., Dexter, T., Detre, S., Salter, J., Smith, I. E., Harris, A. L. and Dowsett, M. (2011). Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer. Clin. Cancer Res. 17, 3005-3012.
35. Ghoussaini, M., Fletcher, O., Michailidou, K., Turnbull, C., Schmidt, M. K., Dicks, E., Dennis, J., Wang, Q., Humphreys, M. K., Luccarini, C. et al.; Netherlands Collaborative Group on Hereditary Breast and Ovarian Cancer (HEBON); Familial Breast Cancer Study (FBCS); Gene Environment Interaction of Breast Cancer in Germany (GENICA) Network; kConFab Investigators; Australian Ovarian Cancer Study Group (2012). Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat. Genet. 44, 312-318.
36. Guise, T. A., Yin, J. J., Taylor, S. D., Kumagai, Y., Dallas, M., Boyce, B. F., Yoneda, T. and Mundy, G. R. (1996). Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98, 1544-1549.
37. Gupta, P. B., Proia, D., Cingoz, O., Weremowicz, J., Naber, S. P., Weinberg, R. A. and Kuperwasser, C. (2007). Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 67, 2062-2071.
38. Guy, C. T., Cardiff, R. D. and Muller, W. J. (1992a). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954-961.
39. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D. and Muller, W. J. (1992b). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89, 10578-10582.
40. Henderson, M. A., Danks, J. A., Slavin, J. L., Byrnes, G. B., Choong, P. F., Spillane, J. B., Hopper, J. L. and Martin, T. J. (2006). Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res. 66, 2250-2256.
41. Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S. et al. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8, R76.
42. Hiratsuka, S., Watanabe, A., Sakurai, Y., Akashi-Takamura, S., Ishibashi, S., Miyake, K., Shibuya, M., Akira, S., Aburatani, H. and Maru, Y. (2008). The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 10, 1349-1355.
43. Hou, Z., Bailey, J. P., Vomachka, A. J., Matsuda, M., Lockefeer, J. A. and Horseman, N. D. (2000). Glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1) is induced by prolactin and suppressed by progesterone in mammary epithelium. Endocrinology 141, 4278-4283.
44. Hu, Z., Fan, C., Oh, D. S., Marron, J. S., He, X., Qaqish, B. F., Livasy, C., Carey, L. A., Reynolds, E., Dressler, L. et al. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96.
45. Huang, Y., Song, N., Ding, Y., Yuan, S., Li, X., Cai, H., Shi, H. and Luo, Y. (2009). Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res. 69, 7529-7537.
46. Hunter, K. W. (2012). Mouse models of cancer: does the strain matter? Nat. Rev. Cancer 12, 144-149.
47. Huper, G. and Marks, J. R. (2007). Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. Cancer Res. 67, 2990-3001.
48. Johnstone, C. N., Castellví-Bel, S., Chang, L. M., Bessa, X., Nakagawa, H., Harada, H., Sung, R. K., Piqué, J. M., Castells, A. and Rustgi, A. K. (2004). ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. Gene 336, 59-71.
49. Kim, H., Watkinson, J., Varadan, V. and Anastassiou, D. (2010). Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med. Genomics 3, 51.
50. Koch, M., Hussein, F., Woeste, A., Gründker, C., Frontzek, K., Emons, G. and Hawighorst, T. (2011). CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res. Treat. 128, 337-346.
51. Kremer, R., Li, J., Camirand, A. and Karaplis, A. C. (2011). Parathyroid hormone related protein (PTHrP) in tumor progression. Adv. Exp. Med. Biol. 720, 145-160.
52. Kuperwasser, C., Hurlbut, G. D., Kittrell, F. S., Dickinson, E. S., Laucirica, R., Medina, D., Naber, S. P. and Jerry, D. J. (2000). Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am. J. Pathol. 157, 2151-2159.
53. Kusuma, N., Anderson, R. L. and Pouliot, N. (2011). Laminin alpha5-derived peptides modulate the properties of metastatic breast tumour cells. Clin. Exp. Metastasis 28, 909-921.
54. Kusuma, N., Denoyer, D., Eble, J. A., Redvers, R. P., Parker, B. S., Pelzer, R., Anderson, R. L. and Pouliot, N. (2012). Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis. Int. J. Cancer 130, 555-566.
55. Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y. and Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750-2767.
56. Lelekakis, M., Moseley, J. M., Martin, T. J., Hards, D., Williams, E., Ho, P., Lowen, D., Javni, J., Miller, F. R., Slavin, J. et al. (1999). A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 17, 163-170.
57. Li, J., Karaplis, A. C., Huang, D. C., Siegel, P. M., Camirand, A., Yang, X. F., Muller, W. J. and Kremer, R. (2011). PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J. Clin. Invest. 121, 4655-4669.
58. Lifsted, T., Le Voyer, T., Williams, M., Muller, W., Klein-Szanto, A., Buetow, K. H. and Hunter, K. W. (1998). Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int. J. Cancer 77, 640-644.
59. Linforth, R., Anderson, N., Hoey, R., Nolan, T., Downey, S., Brady, G., Ashcroft, L. and Bundred, N. (2002). Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. Clin. Cancer Res. 8, 3172-3177.
60. Lister, I. M., Rasmussen, L. K., Johnsen, L. B., Møller, L., Petersen, T. E. and Sørensen, E. S. (1998). The primary structure of caprine PP3: amino acid sequence, phosphorylation, and glycosylation of component PP3 from the proteose-peptone fraction of caprine milk. J. Dairy Sci. 81, 2111-2115.
61. Lochter, A., Galosy, S., Muschler, J., Freedman, N., Werb, Z. and Bissell, M. J. (1997a). Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 139, 1861-1872.
62. Lochter, A., Srebrow, A., Sympson, C. J., Terracio, N., Werb, Z. and Bissell, M. J. (1997b). Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J. Biol. Chem. 272, 5007-5015.
63. Lukanidin, E. and Sleeman, J. P. (2012). Building the niche: the role of the S100 proteins in metastatic growth. Semin. Cancer Biol. 22, 216-225.
64. Madden, S. F., Clarke, C., Gaule, P., Aherne, S. T., O'Donovan, N., Clyne, M., Crown, J. and Gallagher, W. M. (2013). BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res. 15, R52.
65. Martin, M. D., Carter, K. J., Jean-Philippe, S. R., Chang, M., Mobashery, S., Thiolloy, S., Lynch, C. C., Matrisian, L. M. and Fingleton, B. (2008). Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res. 68, 6251-6259.
66. Mongroo, P. S., Johnstone, C. N., Naruszewicz, I., Leung-Hagesteijn, C., Sung, R. K., Carnio, L., Rustgi, A. K. and Hannigan, G. E. (2004). Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer. Oncogene 23, 8959-8970.
67. Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D. and Chodosh, L. A. (2002). Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451-461.
68. Moon, A., Yong, H. Y., Song, J. I., Cukovic, D., Salagrama, S., Kaplan, D., Putt, D., Kim, H., Dombkowski, A. and Kim, H. R. (2008). Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol. Cancer Res. 6, 1544-1553.
69. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R. and Leder, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115.
70. Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L. et al. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10, 5367-5374.
71. Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A. et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
72. Pertschuk, L. P., Eisenberg, K. B., Carter, A. C. and Feldman, J. G. (1985). Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer 55, 1513-1518.
73. Pfefferle, A. D., Herschkowitz, J. I., Usary, J., Harrell, J. C., Spike, B. T., Adams, J. R., Torres-Arzayus, M. I., Brown, M., Egan, S. E., Wahl, G. M. et al. (2013). Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 14, R125.
74. Pontiggia, O., Sampayo, R., Raffo, D., Motter, A., Xu, R., Bissell, M. J., Joffé, E. B. and Simian, M. (2012). The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Res. Treat. 133, 459-471.
75. Pouliot, N., Pearson, H. B. and Burrows, A. (2013). Investigating metastasis using in vitro platforms. In Metastatic Cancer: Integrated Organ System and Biological Approach (ed. R. Jandial). Austin, TX: Landes Bioscience.
76. Prince, J. M., Klinowska, T. C., Marshman, E., Lowe, E. T., Mayer, U., Miner, J., Aberdam, D., Vestweber, D., Gusterson, B. and Streuli, C. H. (2002). Cell-matrix interactions during development and apoptosis of the mouse mammary gland in vivo. Dev. Dyn. 223, 497-516.
77. Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Nieto, M. A. et al. (2005). Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436, 123-127.
78. Ramos-DeSimone, N., Hahn-Dantona, E., Sipley, J., Nagase, H., French, D. L. and Quigley, J. P. (1999). Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274, 13066-13076.
79. Ribas, V., Drew, B. G., Le, J. A., Soleymani, T., Daraei, P., Sitz, D., Mohammad, L., Henstridge, D. C., Febbraio, M. A., Hewitt, S. C. et al. (2011). Myeloid-specific estrogen receptor alpha deficiency impairs metabolic homeostasis and accelerates atherosclerotic lesion development. Proc. Natl. Acad. Sci. USA 108, 16457-16462.
80. Rockwell, S. and Kallman, R. F. (1973). Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. Radiat. Res. 53, 281-294.
81. Russnes, H. G., Navin, N., Hicks, J. and Borresen-Dale, A. L. (2011). Insight into the heterogeneity of breast cancer through next-generation sequencing. J. Clin. Invest. 121, 3810-3818.
82. Sloan, E. K. and Anderson, R. L. (2002). Genes involved in breast cancer metastasis to bone. Cell. Mol. Life Sci. 59, 1491-1502.
83. Sloan, E. K., Pouliot, N., Stanley, K. L., Chia, J., Moseley, J. M., Hards, D. K. and Anderson, R. L. (2006). Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 8, R20.
84. Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S. et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874.
85. Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S. et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100, 8418-8423.
86. Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., Wedge, D. C., Nik-Zainal, S., Martin, S., Varela, I., Bignell, G. R. et al.; Oslo Breast Cancer Consortium (OSBREAC) (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404.
87. Sternlicht, M. D., Lochter, A., Sympson, C. J., Huey, B., Rougier, J. P., Gray, J. W., Pinkel, D., Bissell, M. J. and Werb, Z. (1999). The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137-146.
88. Stewart, T. J. and Abrams, S. I. (2007). Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J. Immunol. 179, 2851-2859.
89. Stierer, M., Rosen, H., Weber, R., Hanak, H., Spona, J. and Tüchler, H. (1993). Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann. Surg. 218, 13-21.
90. Surowiak, P., Dziegiel, P., Matkowski, R., Sopel, M., Wojnar, A., Kornafel, J. and Zabel, M. (2003). Prognostic value of immunocytochemical determination of parathyroid hormone-related peptide expression in cells of mammary ductal carcinoma. Analysis of 7 years of the disease course. Virchows Arch. 442, 245-251.
91. Taube, J. H., Herschkowitz, J. I., Komurov, K., Zhou, A. Y., Gupta, S., Yang, J., Hartwell, K., Onder, T. T., Gupta, P. B., Evans, K. W. et al. (2010). Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 107, 15449-15454.
92. Teschendorff, A. E., Miremadi, A., Pinder, S. E., Ellis, I. O. and Caldas, C. (2007). An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 8, R157.
93. Tester, A. M., Ruangpanit, N., Anderson, R. L. and Thompson, E. W. (2000). MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin. Exp. Metastasis 18, 553-560.
94. The Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70.
95. Tikoo, A., Roh, V., Montgomery, K. G., Ivetac, I., Waring, P., Pelzer, R., Hare, L., Shackleton, M., Humbert, P. and Phillips, W. A. (2012). Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. PLoS ONE 7, e36924.
96. To, K., Fotovati, A., Reipas, K. M., Law, J. H., Hu, K., Wang, J., Astanehe, A., Davies, A. H., Lee, L., Stratford, A. L. et al. (2010). Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced selfrenewal, mammosphere growth, and drug resistance. Cancer Res. 70, 2840-2851.
97. Tomayko, M. M. and Reynolds, C. P. (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148-154.
98. Varticovski, L., Hollingshead, M. G., Robles, A. I., Wu, X., Cherry, J., Munroe, D. J., Lukes, L., Anver, M. R., Carter, J. P., Borgel, S. D. et al. (2007). Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin. Cancer Res. 13, 2168-2177.
99. Vichai, V. and Kirtikara, K. (2006). Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1, 1112-1116.
100. Voduc, K. D., Cheang, M. C., Tyldesley, S., Gelmon, K., Nielsen, T. O. and Kennecke, H. (2010). Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28, 1684-1691.
101. Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A., Nacken, W., Foell, D., van der Poll, T., Sorg, C. et al. (2007). Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042-1049.
102. Wang, H., Mohammad, R. M., Werdell, J. and Shekhar, P. V. (1998). p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: in vitro versus in vivo activity. Int. J. Mol. Med. 1, 915-923.
103. Weigelt, B., Mackay, A., A'hern, R., Natrajan, R., Tan, D. S., Dowsett, M., Ashworth, A. and Reis-Filho, J. S. (2010). Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 11, 339-349.
104. Welsh, A. W., Lannin, D. R., Young, G. S., Sherman, M. E., Figueroa, J. D., Henry, N. L., Ryden, L., Kim, C., Love, R. R., Schiff, R. et al. (2012). Cytoplasmic estrogen receptor in breast cancer. Clin. Cancer Res. 18, 118-126.
105. Wynford-Thomas, D. (1992). P53 in tumour pathology: can we trust immunocytochemistry? J. Pathol. 166, 329-330.
106. Yemelyanova, A., Vang, R., Kshirsagar, M., Lu, D., Marks, M. A., Shih, IM. and Kurman, R. J. (2011). Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod. Pathol. 24, 1248-1253.
107. Yerlikaya, A. and Erin, N. (2008). Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int. J. Mol. Med. 22, 817-823.
108. Yoshida, A., Nakamura, Y., Shimizu, A., Harada, M., Kameda, Y., Nagano, A., Inaba, M. and Asaga, T. (2000). Significance of the parathyroid hormone-related protein expression in breast carcinoma. Breast Cancer 7, 215-220.
109. Zetter, B. R. (1993). Adhesion molecules in tumor metastasis. Semin. Cancer Biol. 4, 219-229.